- Home
- ACM vs BIIB Comparison
ACM vs BIIB Comparison
Compare ACM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- BIIB
- Stock Information
- Founded
- ACM 1980
- BIIB 1978
- Country
- ACM United States
- BIIB United States
- Employees
- ACM N/A
- BIIB N/A
- Industry
- ACM Military/Government/Technical
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- BIIB Health Care
- Exchange
- ACM Nasdaq
- BIIB Nasdaq
- Market Cap
- ACM 17.6B
- BIIB 24.2B
- IPO Year
- ACM 2007
- BIIB 1991
- Fundamental
- Price
- ACM $132.02
- BIIB $165.01
- Analyst Decision
- ACM Strong Buy
- BIIB Buy
- Analyst Count
- ACM 10
- BIIB 24
- Target Price
- ACM $135.10
- BIIB $174.62
- AVG Volume (30 Days)
- ACM 780.8K
- BIIB 1.8M
- Earning Date
- ACM 11-17-2025
- BIIB 10-30-2025
- Dividend Yield
- ACM 0.79%
- BIIB N/A
- EPS Growth
- ACM 147.22
- BIIB N/A
- EPS
- ACM 4.59
- BIIB 10.97
- Revenue
- ACM $16,074,699,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- ACM $2.09
- BIIB $2.97
- Revenue Next Year
- ACM $5.05
- BIIB N/A
- P/E Ratio
- ACM $28.74
- BIIB $15.01
- Revenue Growth
- ACM 1.50
- BIIB 4.77
- 52 Week Low
- ACM $85.00
- BIIB $110.04
- 52 Week High
- ACM $135.52
- BIIB $169.00
- Technical
- Relative Strength Index (RSI)
- ACM 51.78
- BIIB 68.22
- Support Level
- ACM $131.39
- BIIB $151.83
- Resistance Level
- ACM $135.52
- BIIB $169.00
- Average True Range (ATR)
- ACM 2.67
- BIIB 5.78
- MACD
- ACM -0.06
- BIIB 1.25
- Stochastic Oscillator
- ACM 57.63
- BIIB 86.52
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).